manufacturer's information for use and the FDA indications. 4 -2 7 A recently convened FDA Circulatory System Devices Advisory Panel reviewed the broader use of drugeluting stents in real-world clinical use and the implications of using drug-eluting stents outside of their approved indications. The panel concluded that there is a need for a comprehensive assessment of the safety and efficacy of off-label use of drugeluting stents. 28 To date, the frequency of use and the safety and effectiveness of using drug-eluting stents for off-label and untested indications have not been systematically evaluated by either the pivotal drug-eluting stent trials or by any large registries within or outside of the United States. Therefore, we evaluated the frequency, effectiveness, and safety of off-label and untested use of drug-eluting stents compared with standard use in a prospective, multicenter registry.
METHODS
The D.E.S.cover Registry is a prospective, multicenter, observational study conducted at 140 US academic and community hospitals and consists of 7752 patients who underwent percutaneous coronary intervention (PCI) between January and June 2005. Participants included consecutive patients undergoing PCI who provided written informed consent.
The registry did not specify PCI treatment protocols. Baseline characteristics, clinical and angiographic features, and procedural and clinical events were assessed. Clinical outcomes were determined during hospitalization and at 30 days, 6 months, and 1 year after discharge. Follow-up included assessment for the occurrence of major adverse events, including myocardial infarction (MI), PCI, coronary artery bypass graft (CABG) surgery, death (both cardiac and noncardiac), and stent thrombosis.
Patient data were collected using standardized Internet-based electronic case report forms anonymously coded to protect the identity of study participants. An independent research organization served as the administrator for the study, sponsored by Cordis Corp. The University of Pittsburgh served as the statistical analysis core. Institutional review board approval was obtained at all participating centers.
Study Population
The source population consisted of the 7752 patients in the D.E.S.cover Registry. Of these, 7023 (91%) received at least 1 drug-eluting stent, 6993 (90%) received sirolimus-or paclitaxeleluting stents, 6706 (87%) received only a drug-eluting stent and no baremetal stent, and 5851 (75%) did not receive any other device in addition to drug-eluting stent (eg, received atherectomy). Among these 5851 patients, who received sirolimus-or paclitaxeleluting stents only, off-label and untested use could be determined in 5541 (95%), which constituted the study cohort.
Definitions
For the sirolimus-and paclitaxeleluting stents, use was defined as standard, off-label, or untested based on the manufacturers' information for use. All definitions were based on lesion criteria. The information for use for the sirolimus-eluting stent states that "indicated use is for disease due to discrete de novo lesions of length Յ30 mm in the native coronary arteries with a reference vessel diameter Ն2.5 mm to Յ3.5 mm." 29 For the paclitaxel-eluting stent, indicated use is "treatment of de novo lesions Յ28 mm in length in native coronary arteries Ն2.5 mm to Յ3.75 mm in diameter."
30 Use of drug-eluting stents that met the above criteria constituted the standard group.
Based on the information for use, offlabel use for the sirolimus-eluting stent was defined as stenting of a restenotic lesion, lesion in a bypass graft, lesion length greater than 30 mm, or reference-vessel diameter less than 2.5 mm or greater than 3.5 mm. For the paclitaxel-eluting stent, the lesion criteria were identical except for lesion length greater than 28 mm and referencevessel diameter less than 2.5 mm or greater than 3.75 mm.
For both stent types, untested use was defined by the information for use that states that the safety and effectiveness has not been established for the treatment of left main, ostial, bifurcation, or totally occluded lesions. Use in the presence of acute MI was defined as offlabel, untested, or standard, based on lesion characteristics and not the presence of MI per se. Patients with treated lesions meeting the definition for both off-label and untested use of drugeluting stents were classified in the offlabel category. Direct stenting was defined as stent deployment without predilatation.
Operators were required to report the "planned" or "intended" duration of clopidogrel therapy at time of hospital discharge. Patients were categorized as receiving "standard" clopidogrel administration if they were prescribed therapy for 3 months (sirolimus-eluting stents) and 6 months (paclitaxel-eluting stents) as recommended by the manufacturers' information for use. Those who were prescribed clopidogrel beyond this period were categorized as receiving "prolonged" clopidogrel administration.
Definitions of Adverse Events
Stent thrombosis included either definite or probable stent thrombosis. Definite stent thrombosis was defined as presence of angiographic thrombus in a stent that previously had been successfully deployed, accompanied by an acute coronary syndrome. Angiographic thrombus was defined as complete occlusion (TIMI [Thrombolysis in Myocardial Infarction] grade 0 or 1 flow), with a stent diameter stenosis less than 30% or evidence of flow-limiting thrombus (ovoid or linear filling defect) within or immediately adjacent to the stent. Probable stent thrombosis was defined as unexplained sudden cardiac death or Q-wave MI in the distribution of the stented artery.
Myocardial infarction included Qwave MI or non-Q-wave MI and was defined as in the pivotal trials.
1,2 Stent thrombosis and MI were adjudicated by an independent committee.
Primary Outcomes
To assess the effectiveness of use of drug-eluting stents for off-label and untested indications, the primary outcome was 1-year target vessel repeat revascularization (TVR) achieved via PCI or CABG surgery. To assess the safety of off-label and untested use of drug-eluting stents, the primary outcome was the composite end point of death, MI, or stent thrombosis at in-hospital, 30-day, and 1-year follow-up.
Statistical Methods
Patient characteristics pertaining to the index PCI, including demographics, medical history, cardiac presentation, periprocedural medications, procedural characteristics, and outcomes were compared between the 3 study groups (standard, untested, and off- In multivariable analysis, missing values were imputed by the mean from nonmissing observations, assuming that less than 7% of the data were missing. 32 Because the proportional hazards assumption of invariant relative risk was not upheld for some clinical outcomes assessed, separate models were fit for 1-year outcomes that excluded patients with events that occurred within the first 30 days.
Statistical analyses were performed using SAS version 9.0 (SAS Institute Inc, Cary, NC), with PϽ.05 (2-sided) considered statistically significant. 
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RESULTS
Patient Population
The study population consisted of 5541 patients who received sirolimus-or paclitaxel-eluting stents only ( 
Observed 1-Year Event Rates
At 1-year follow-up, compared with patients receiving drug-eluting stents for standard indications, those receiving stents for off-label indications had significantly higher rates of death (4.3% vs 2.6%, PϽ.01), TVR via PCI or CABG surgery (7.6% vs 4.4%, PϽ.001) (FIGURE 1) , and the composite end point of death, MI, or stent thrombosis (6.9% vs 4.3%, PϽ.001) ( Table 3 ). For untested indications, the rate of death or MI was similar to that for standard indications (4.1% vs 4.2%). However, the 1-year rate of TVR via PCI or CABG surgery (6.7% vs 4.4%) was significantly higher with untested use. Although the 1-year rate of stent thrombosis was 2-fold higher for off-label use (0.7%) and 3-fold higher for untested use (0.9%) compared with standard use (0.3%), the absolute rates were low (Ͻ1% for all 3 groups).
Adjusted HRs
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Off-Label Untested Standard
Target vessel revascularization was achieved via percutaneous coronary intervention or coronary artery bypass graft surgery. See "Methods" section for definitions of standard, off-label, and untested use of drugeluting stents. 
Subgroup Analyses
Higher early risk of death, MI, or stent thrombosis and higher 1-year risk of repeat TVR associated with untested and off-label use of drug-eluting stents were observed among certain subgroups, including those with or without acute MI as a procedure indication, history of prior revascularization, and renal insufficiency (data not shown). The 1-year risk of TVR among the untested and offlabel groups was similar for the sirolimus-eluting stents (n = 3298) (untested use: adjusted HR, 1.55; 95% CI, 1.04-2.31; P = .31; off-label use: adjusted HR, 1.60; 95% CI, 1.12-2.28; P = .009) as well as the paclitaxeleluting stents (n=2243) (untested use: adjusted HR, 1.40; 95% CI, 0.87-2.26; P=.17; off-label use: adjusted HR, 1.36; 95% CI, 0.86-2.18; P=. 19) . However, among patients in the off-label group, the 1-year risk of death, MI, or stent thrombosis was higher only for those receiving a paclitaxel-eluting stent (adjusted HR, 1.83; 95% CI, 1.21-2.76; P=.005) but not for those receiving a sirolimus-eluting stent (adjusted HR, 0.98; 95% CI, 0.67-1.43; P=.91).
Associations of Outcomes With Antiplatelet Therapies
For patients receiving drug-eluting stents for off-label indications, the risk of TVR was not different according to whether recommended clopidogrel use was standard, ie, 3 months for sirolimus-eluting stents and 6 months for paclitaxel-eluting stents (observed 1-year rate, 7.0% [23/327] ; HR, 1.38; 95% CI, 0.75-2.54; P = .31) or prolonged (observed 1-year rate, 6.8% [71/1051]; HR, 1.44; 95% CI, 1.04-1.98; P = .03). In contrast, among patients in the off-label group, the risk of death, MI, or stent thrombosis at 1 Abbreviations: CABG, coronary artery bypass graft; CI, confidence interval; MI, myocardial infarction; PCI, percutaneous coronary intervention; TLR, target lesion revascularization; TVR, target vessel revascularization. *Adjusted for combinations of age, sex, geographic region within United States, procedure priority, history of MI, PCI, coronary heart failure, peripheral vascular disease, renal insufficiency, diabetes, or pulmonary disease, current smoker, number of vessels with 50% or greater stenosis, ␤-blocker before PCI, procedural use of clopidogrel/ticlopidine, number of attempted lesions, number of successfully treated lesions, lesion complication.
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COMMENT
In this study, the frequency and outcomes of off-label or untested use of drug-eluting stents compared with standard use were evaluated from a large, multicenter, prospective PCI registry. We observed that approximately half of all use of drug-eluting stents occurs in off-label or untested settings. Compared with patients receiving drug-eluting stents for standard indications, those receiving such stents for off-label and untested indications tended to present with more severe clinical profiles, which would have excluded these patients from the pivotal randomized trials that led to FDA approval of drug-eluting stents. [1] [2] [3] These findings likely reflect the broader patient mix encountered in real-world practice compared with randomized controlled trials. Our data indicate that patients treated with drug-eluting stents in the United States are similar to such patients in registries outside of the United States. [6] [7] [8] [9] Therefore, our findings are likely to be broadly applicable to PCI with drugeluting stent insertion performed within and outside the United States. Although off-label and untested use involved more complex anatomy, including multilesion stenting, a high degree of angiographic success occurred in patients receiving drug-eluting stents for off-label (1551 [98.5%]), untested (1475 [98.0%]), and standard (4380 [99.5%]) indications. This indicates widespread interventionist proficiency and stent performance in treating a variety of lesion and clinical subtypes. In addition, the rate of inhospital death, MI, or stent thrombosis was less than 1% for each group. Nevertheless, a 2-fold increase was observed among off-label and untested patient groups. It is not known whether modification or refinement of procedural approaches or techniques, or augmentation of ancillary medical therapy, can affect this difference.
A significant difference in clinical outcome for patients in the off-label group was clearly evident by 30-day follow-up. Both observed and adjusted analyses indicated a greater than 2-fold higher risk of death, MI, or stent thrombosis. This increase was a result of more frequent events among each of the individual end points. A precise explanation for this difference in outcome is not apparent from our study. One might suspect that the off-label group might have had more severe noncardiac illness or possibly acute MI as a procedural indication, but our data do not support this explanation. Although the absolute rate of this composite safety end point was only 2.5%, clinicians should be aware of this difference for patients receiving drug-eluting stents for off-label indications and include this consideration when selecting treatment strategies for such patients.
At 1 year, a difference in mortality and in the composite safety end point was observed among those in the off-label group. Following adjustment, however, this difference was not different compared with the other groups. This result suggests there were factors other than off-label use that accounted for the excess rates of adverse events. Furthermore, the cumulative incidence of stent thrombosis was low (Ͻ1%) among all 3 groups. Thus, in terms of safety concerns, these findings are reassuring in regard to the broader application of drugeluting stents.
A significant difference in TVR was demonstrated both for the off-label and the untested groups compared with the standard group. We observed an increased need for TVR (1.5-fold increase), driven primarily by increased need for repeat PCI but not CABG surgery (Figure 2) . Again, the absolute 1-year rates remained low, The impact of duration of prolonged dual antiplatelet therapy is an important consideration for the safety of drug-eluting stents. Previous data have indicated that premature discontinuation of antiplatelet therapy after use of drug-eluting stents contributes to stent thrombosis. 33 Moreover, prolonged duration of dual antiplatelet therapy with aspirin and clopidogrel has been associated with a reduced risk of death and death or MI after use of drugeluting stents. 34 Our data indicate that there may be an increased risk of death, MI, or stent thrombosis seen at 1 year confined to patients in the off-label group, which received a standard clopidogrel recommendation (3 or 6 months for sirolimus-or paclitaxeleluting stents, respectively) that may be obviated by prolonged dual antiplatelet therapy.
We observed an increased hazard of the composite of death, MI, or stent thrombosis at 1 year associated with offlabel use of the paclitaxel-but not the sirolimus-eluting stent. This difference could be related to the type of antirestenotic drugs used or to the duration of drug release. On the other hand, although this apparent difference in safety may be real, we cannot exclude that this finding occurred by chance alone or is due to an unmeasurable selection bias for a particular drugeluting stent.
Study Limitations
The present registry is observational and did not randomly assign patients to standard, off-label, or untested use of drug-eluting stents. Clopidogrel use was not recorded during follow-up, but we did record prescribed duration of clopidogrel therapy following PCI. A meaningful and unbiased comparison of drug-eluting compared with bare-metal stents for off-label and untested indications was not possible in the D.E.S.cover Registry, since only 5% (n=388) of patients received baremetal stents, and the clinical and angiographic characteristics of these patients are very different from the characteristics of those who received drug-eluting stents.
CONCLUSIONS
Our findings indicate that off-label and untested use of drug-eluting stents is widespread. Compared with standard use, short-term outcomes appear to be worse with off-label and untested use. However, even with off-label or untested use of drug-eluting stents, overall absolute event rates both inhospital and at 12 months following PCI remain relatively low.
